SCHEMBL1955723

SCHEMBL1955723

CC1(C)CCC(CN2CCN(c3ccc(C(=O)N[S+]([O-])c4ccc(NN5CCCCC5)c([N+](=O)[O-])c4)c(Oc4cccc5[nH]ccc45)c3)CC2)=C(c2ccc(Cl)cc2)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1955725 0.91 — —
SCHEMBL1957665 0.87 BCL2 (0.69) —
SCHEMBL1954866 0.87 BCL2 (0.72) —
SCHEMBL1959450 0.86 BCL2 (0.64) —
SCHEMBL1957831 0.86 BCL2 (0.86) —
SCHEMBL1955481 0.86 BCL2 (0.83) —
SCHEMBL1959519 0.85 BCL2 (0.82) —
SCHEMBL1958209 0.83 — —
SCHEMBL1959119 0.83 BCL2 (0.83) —
SCHEMBL1958650 0.83 BCL2 (0.71) —

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2507229-A1 SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES Abbott Laboratories (US) 2012-10-10 — — EP disclosed
WO-2011068561-A1 SULFONAMIDE DERIVATIVES AS BCL-2-SELECTIVE APOPTOSIS-INDUCING AGENTS FOR THE TREATMENT OF CANCER AND IMMUNE DISEASES ABBOTT LABORATORIES (US) 2011-06-09 — — WO disclosed
Send feedback